Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers [0.03%]
针对淋巴瘤的ROR1靶向治疗药物Zilovertamab Vedotin
Michael L Wang,Jacqueline C Barrientos,Richard R Furman et al.
Michael L Wang et al.
BACKGROUND: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate comprising a monoclonal antibody recognizing extracellular ROR1, a ...
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease [0.03%]
低剂量白介素-2对缺血性心脏病调节T细胞反应的影响
Tian X Zhao,Rouchelle S Sriranjan,Zewen Kelvin Tuong et al.
Tian X Zhao et al.
BACKGROUND: Atherosclerosis is a chronic inflammatory disease of the artery wall. Regulatory T cells (Tregs) limit inflammation and promote tissue healing. Low doses of interleukin (IL)-2 have the potential to increase Tregs, but its use is...
Clinical Trial
NEJM evidence. 2022 Jan;1(1):EVIDoa2100009. DOI:10.1056/EVIDoa2100009 2022
Real-Time Artificial Intelligence-Based Optical Diagnosis of Neoplastic Polyps during Colonoscopy [0.03%]
实时人工智能结肠镜检查期间对新生物息肉的光学诊断
Ishita Barua,Paulina Wieszczy,Shin-Ei Kudo et al.
Ishita Barua et al.
BACKGROUND: Artificial intelligence using computer-aided diagnosis (CADx) in real time with images acquired during colonoscopy may help colonoscopists distinguish between neoplastic polyps requiring removal and nonneoplastic polyps not requ...
H Gilbert Welch,Adewole S Adamson
H Gilbert Welch
Should Recommendations for Cancer Screening Differentiate on Race?Cancer screening recommendations routinely differentiate among individuals on the basis of their age. Starting and stopping ages are an attempt to hit the screening sweet spo...
Data and Safety Monitoring Board Monitoring of Clinical Trials for Early Efficacy [0.03%]
临床试验早期疗效的数据和安全监测委员会监察
Lori E Dodd,Michael A Proschan
Lori E Dodd
DSMB Monitoring of Clinical Trials for Early EfficacyIn this article in the NEJM Evidence DSMB mini-series, Dodd and Proschan review the clinical, ethical, and statistical issues that confront a DSMB when trial data suggest that the treatme...
Marc A Pfeffer,Brian Claggett
Marc A Pfeffer
Behind the Scenes of TOPCAT - Bending to InformWhen investigators in a 2013 RCT received their unblinded results, the data forced them to make a difficult decision - do they stay within conventional guidelines for data analysis or forge a n...
Sagori Mukhopadhyay,Karen M Puopolo
Sagori Mukhopadhyay
Global mortality among children younger than 5 years of age has decreased since 1990, yet it remains unacceptably high in low- and middle-income countries, particularly in the World Health Organization's African region.1 Infectious diseases...
Evaluation of Trends in Knee Arthroscopy from 2004 to 2019 in Ontario, Canada [0.03%]
对加拿大安大略省从2004年到2019年的膝关节镜手术发展趋势的评估
Y Raja Rampersaud,Mayilee Canizares,Michael G Zywiel et al.
Y Raja Rampersaud et al.
BACKGROUND: How changes in recommendations for the use of knee arthroscopy have influenced real-world practice remains unclear. We assessed temporal trends in knee arthroscopy volume, costs, and rates of progression to knee arthroplasty fol...
Pavan K Bendapudi
Pavan K Bendapudi
Warfarin Versus Direct Oral AnticoagulantsDespite the growing popularity of DOACs, data in specific populations have provided a stark reminder that the equivalence (or superiority) of DOACs to warfarin cannot be assumed across the board. Th...
Thomas Cook,Olive D Buhule
Thomas Cook
Stopping Trials Early Due to HarmDSMBs protect clinical trial participants from harm. We describe two trials stopped for potential harm to enrollees: a DSMB recommended termination soon after enrollment began when data showed higher mortali...